By Katherine Hamilton

AnaptysBio is spinning off its biopharmaceutical operations into a separate public company as soon as late April.

The clinical-stage biotechnology company said Tuesday it plans to separate the biopharma portfolio from its royalty assets during the second quarter of 2026.

The royalty management company will initially retain the name AnaptysBio, as well as the ticker ANAB on the Nasdaq, and will manage the financial collaborations from Jemperli with GSK and imsidolimab with Vanda.

Daniel Faga is anticipated to be the initial chief executive of the royalty management company, though specific decisions about the board composition and leadership will be disclosed later, AnaptysBio said.

The spinoff will be called First Tracks Biotherapeutics, and will trade under the ticker TRAX on the Nasdaq. It will focus on the development and potential commercialization of immunology treatments.

Faga will also be chief executive of First Tracks Biotherapeutics to start.

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

March 03, 2026 17:08 ET (22:08 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.